Literature DB >> 33592901

A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?

Miriam Dellino1, Giulio Gargano1, Raffele Tinelli2, Carmine Carriero3, Carla Minoia4, Skrypets Tetania5, Erica Silvestris1, Vera Loizzi6, Angelo Paradiso7, Porzia Casamassima8, Antonio Tufaro9, Gennaro Cormio6, Vito Michele Garrisi8.   

Abstract

ABSTRACT: Paget disease is a complex disorder that can be identified in the breast (mammary Paget disease) or in other locations (extramammary Paget's disease) such as ano-genital skin (Paget disease of the vulva -PVD). This condition is associated with low mortality, but a late diagnosis and recurrence can negatively impact the prognosis. Therefore, the main objective of this study is to evaluate if the human epididymis protein 4 (HE4) and cancer antigen125 (CA125) can promote recognition of PVD in early stages and during the relapses.we have conducted a prospective, observational and laboratory-based study, that included 50 patients, whose 25 healthy women represented the control group and 25 PVD patients, which have been operated in our Oncology Institute, from May 2017 to September 2019. Both in the control group and in PVD patients, the CA-125 and HE4 were evaluated before surgery and after 6 months. Finally, a comparison of markers serum level, both between before/after surgery and with control group, and a ROC (Receiver Operating Characteristic) curve were performed.Dosing the markers in PVD patients, 3/25 (12%) showed a higher value of CA125 and 11/25 (44%) an increased HE4. In addition, after surgical treatment there were no statistically significant difference between levels of CA-125 (P = .3) and HE4 (P = .19). On the other hand, comparing HE4 in PVD patients with the control group, a statistically significant difference was found (P-value = .0036). Contrary, comparing CA-125 in PVD patients with the control group (P-value= .1969), no statistically significant difference was evidenced. Moreover, ROC (Receiver Operating Characteristic) curve showed low sensitivity and specificity for CA125 with area under curve (AUC) = 0.5608. Instead, the ROC curve of HE4 revealed a sensitivity and specificity of 76% and 88% respectively (AUC = 0.7408) using a cut-off at 90 pmol/L.Despite the limited cases, our data showed that CA125 is not a sensitive marker for PVD. On the other hand, in 44% of PVD we've seen an increase in HE4. So, this could be a starting point for further research that could confirm the possibility to use this marker in order to support PVD early identification.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33592901      PMCID: PMC7870238          DOI: 10.1097/MD.0000000000024485

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  22 in total

1.  Benign conditions associated with raised serum CA-125 concentration.

Authors:  P Buamah
Journal:  J Surg Oncol       Date:  2000-12       Impact factor: 3.454

2.  Human epydidimis protein 4 (HE4): could it be useful in the diagnosis of vulvar cancer?

Authors:  M Montagnana; G Lippi; E Danese; O Ruzzenente; M Franchi; G C Guidi
Journal:  Clin Lab       Date:  2010       Impact factor: 1.138

Review 3.  Management of presumed benign ovarian tumors: updated French guidelines.

Authors:  J-L Brun; X Fritel; Y Aubard; B Borghese; N Bourdel; N Chabbert-Buffet; P Collinet; X Deffieux; G Dubernard; C Huchon; N Kalfa; N Lahlou; H Marret; C Pienkowski; H Sevestre; I Thomassin-Naggara; J Levêque
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2014-10-18       Impact factor: 2.435

Review 4.  Extramammary Paget's Disease.

Authors:  Mackenzie Asel; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2019-02       Impact factor: 3.722

Review 5.  Breast cancer: an update on treatment-related infertility.

Authors:  Erica Silvestris; Miriam Dellino; Paola Cafforio; Angelo Virgilio Paradiso; Gennaro Cormio; Stella D'Oronzo
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-31       Impact factor: 4.553

6.  Primary Vaginal Carcinoma Arising on Cystocele Mimicking Vulvar Cancer.

Authors:  Miriam Dellino; Carmine Carriero; Erica Silvestris; Teresa Capursi; Angelo Paradiso; Gennaro Cormio
Journal:  J Obstet Gynaecol Can       Date:  2020-04-06

7.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Authors:  Ronny Drapkin; Hans Henning von Horsten; Yafang Lin; Samuel C Mok; Christopher P Crum; William R Welch; Jonathan L Hecht
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

8.  Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?

Authors:  Marut Yanaranop; Vahcharapot Anakrat; Somchai Siricharoenthai; Saranyu Nakrangsee; Bandit Thinkhamrop
Journal:  Gynecol Obstet Invest       Date:  2016-05-21       Impact factor: 2.031

9.  Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Mona Aarenstrup Karlsen; Noreen Sandhu; Claus Høgdall; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Svend A Engelholm; Anette T Pedersen; Dorthe Hartwell; Magnus Lydolph; Inga Alice Laursen; Estrid V S Høgdall
Journal:  Gynecol Oncol       Date:  2012-07-24       Impact factor: 5.482

10.  Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites.

Authors:  Haijun Yao; Minkai Xie; Shibo Fu; Jianhua Guo; Yubing Peng; Zhikang Cai; Yueqing Jiang; Dachao Zheng; Zhong Wang
Journal:  BMC Cancer       Date:  2018-04-10       Impact factor: 4.430

View more
  1 in total

Review 1.  Roles of Antimicrobial Peptides in Gynecological Cancers.

Authors:  Chongyi Zhao; Shuo Yan; Yuzhu Song; Xueshan Xia
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.